^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YIV-906

    i
    Other names: YIV-906, PHY 906, PHY906, KD018, YIV906, PHY-906
    Associations

    News

    Trials
    Company:
    Sanofi, Yiviva
    Drug class:
    MMP inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P2, N=62, Completed, Yiviva Inc. | Recruiting --> Completed | N=125 --> 62 | Trial completion date: May 2024 --> Nov 2024
    Trial completion • Enrollment change • Trial completion date
    |
    sorafenib • YIV-906
    3years
    YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity. (PubMed, Front Pharmacol)
    In conclusion, YIV-906 modulates adaptive immunity by activating T effector cells mainly through its action on SHP1/2. YIV-906 could also facilitate immune checkpoint blockade therapy or CAR-T cell therapy for cancer treatment.
    Journal • CAR T-Cell Therapy • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
    |
    PD-L1 (Programmed death ligand 1) • CD19 (CD19 Molecule) • CD69 (CD69 Molecule) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
    |
    PD-L1 overexpression • PD-1 overexpression • CD19 expression
    |
    YIV-906
    almost4years
    YIV-906 could modulate nuclear factor of activated T-cells (NFAT) activity of T cells for immune checkpoint blockade therapy and CAR T-cell therapy (AACR 2022)
    Currently, a phase II international clinical trial for using YIV-906 plus sorafenib to target HBV positive hepatocellular carcinoma as first line therapy (NCT04000737) had been initialized. This is worthy of further investigation. (Supported by research fund from Yiviva, inc)
    CAR T-Cell Therapy • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • CD69 (CD69 Molecule) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
    |
    sorafenib • YIV-906
    over4years
    YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. (PubMed, Sci Rep)
    Flavonoids from YIV-906 were responsible for modulating IDO activity and potentiating IFNg action in M1-like macrophage polarization. In conclusion, YIV-906 could act as an immunomodulator and enhance the innate and adaptive immune response and potentiate anti-tumor activity for immunotherapies to treat cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • IL4 (Interleukin 4)
    |
    YIV-906
    5years
    WGCNA reveals key gene modules regulated by the combined treatment of colon cancer with PHY906 and CPT11. (PubMed, Biosci Rep)
    In conclusion, a total of 18 key genes were identified in this study. These genes showed strong correlation with PHY906-CPT11 treatment in colon cancer, which may help elucidate the underlying molecular mechanism of PHY906-CPT11 treatment in colon cancer.
    Journal
    |
    TARDBP (TAR DNA Binding Protein) • DDX5 (DEAD-Box Helicase 5)
    |
    irinotecan • YIV-906
    over5years
    A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. (PubMed, Oncologist)
    Our data showed that PHY906 increases the therapeutic index of capecitabine by enhancing its antitumor activity and reduces its toxicity profile in advanced HCC.
    Clinical • P2 data • Journal • Combination therapy
    |
    AFP (Alpha-fetoprotein)
    |
    capecitabine • YIV-906